| Literature DB >> 31009957 |
Vu Van Khien1, Duong Minh Thang1, Tran Manh Hai2,3, Nguyen Quang Duat4, Pham Hong Khanh4, Dang Thuy Ha5, Tran Thanh Binh6, Ho Dang Quy Dung6, Tran Thi Huyen Trang2, Yoshio Yamaoka7.
Abstract
Antibiotic resistance is the most important factor leading to the failure of eradication regimens. This review focuses on the prevalence of Helicobacter pylori primary and secondary resistance to clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug in Vietnam. We searched the PubMed, EMBASE, Vietnamese National Knowledge Infrastructure, and Vietnamese Biomedical databases from January 2000 to December 2016. The search terms included the following: H. pylori infection, antibiotic (including clarithromycin, metronidazole, amoxicillin, levofloxacin, tetracycline, and multidrug) resistance in Vietnam. The data were summarized in an extraction table and analyzed manually. Finally, Excel 2007 software was used to create charts. Ten studies (three studies in English and seven in Vietnamese) were included in this review. A total of 308, 412, 523, 408, 399, and 268 H. pylori strains were included in this review to evaluate the prevalence of H. pylori primary resistance to amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance, respectively. Overall, the primary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 15.0%, 34.1%, 69.4%, 27.9%, 17.9% and 48.8%, respectively. Secondary resistance rates of amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline, and multidrug resistance were 9.5%, 74.9%, 61.5%, 45.7%, 23.5% and 62.3%, respectively. In Vietnam, primary and secondary resistance to H. pylori is increasing over time and affects the effectiveness of H. pylori eradication.Entities:
Keywords: Amoxicillin; Bismuth; Clarithromycin; Helicobacter pylori; Metronidazole
Mesh:
Substances:
Year: 2019 PMID: 31009957 PMCID: PMC6743798 DOI: 10.5009/gnl18137
Source DB: PubMed Journal: Gut Liver ISSN: 1976-2283 Impact factor: 4.519
Fig. 1Map of Vietnam with three different regions: North, Central, and South. Note: North Vietnam includes northwestern, northeast and Red River Delta areas. Central Vietnam includes north central coast, south central coast and central highlands. South Vietnam includes southeastern and Mekong River Delta areas. Reprinted with the permission of Nations Online Project.
Results of Helicobacter pylori Eradication in Triple First-Line Therapy in Vietnam
| Author | Local | Year | Regimens | Patient (n) | Time (day) | Method | |
|---|---|---|---|---|---|---|---|
| Mao | North | 2000 | OAC | 54 | 10 | PyloriTek test & histology | 91.0 |
| R*AC | 45 | 10 | PyloriTek test & histology | 96.0 | |||
| Hai | North | 2002 | EAC | 53 | 10 | CLO test & histology | 98.1 |
| Vinh | North | 2003 | OAC | 59 | 7 | PyloriTek test & histology | 91.7 |
| OAM | 57 | 7 | PyloriTek test & histology | 73.9 | |||
| OMC | 58 | 7 | PyloriTek test & histology | 82.2 | |||
| Duat | North | 2007 | PAC | 106 | 7 | CLO test | 95.8 |
| Tiep | North | 2008 | RAC | 36 | 7 | CLO test & histology | 91.6 |
| Thang | North | 2010 | EAC | 30 | 7 | CLO test | 90.0 |
| EAC | 30 | 7 | CLO test | 93.3 | |||
| Vinh | North | 2014 | EAC | 162 | 10 | HpFast test & histology | 67.9 |
| Huong and Thang | Central | 2007 | EAC | 77 | 7 | CLO test & histology | 90.0 |
| Nho | Central | 2011 | EAC | 72 | 14 | CLO test & histology | 84.7 |
| Ngoi | South | 2009 | OAC | 35 | 14 | CLO test & histology | 68.5 |
| OAL | 35 | 14 | CLO test & histology | 88.2 | |||
| Trung | South | 2009 | EAC | 43 | 7 | CLO test & UBT | 68.3 |
| EAL | 38 | 10 | CLO test & UBT | 70.2 | |||
| Hoang | South | 2011 | PAC | 80 | 10 | CLO test & histology | 62.8 |
A, amoxicillin; C, clarithromycin; E, esomeprazole; M, metronidazole; L, levofloxacin; R, rabeprazole; P, pantoprazole; O, omeprazole; R*, ranitidine bismuth citrate; CLO test, campylobacter-like organism test; UBT, urease breath test.
Results of Helicobacter pylori Eradication by the Second Treatment Regimen in Vietnam
| Author | Local | Year | Regimens | Patient (n) | Time (day) | Methods | |
|---|---|---|---|---|---|---|---|
| Trung | South | 2008 | EAL | 19 | 10 | CLO test & UBT | 58.8 |
| EBMT | 26 | 14 | CLO test & UBT | 95.7 | |||
| Vinh | North | 2011 | EAC | 31 | 10 | PyloriTek test & histology | 80.7 |
| EBMT | 45 | 14 | PyloriTek test & histology | 86.7 | |||
| Hue | South | 2016 | EBMT | 166 | 10 | E-test & histology | 89.3 |
| Di and Thang | Central | 2012 | EAL | 101 | 10 | CLO test & histology | 83.2 |
| Thang and Anh | Central | 2015 | RLTi | 59 | 7 | CLO test & histology | 86.3 |
A, amoxicillin; B, bismuth; C, clarithromycin; E, esomeprazole; M, metronidazole; L, levofloxacin; R, rabeprazole; T, tetracycline; Ti, tinidazole; UBT, urea breath test; CLO test, campylobacter-like organism test.
Rate of Primary Antibiotic Resistance of Helicobacter pylori in Vietnam (2001–2016)
| Author/strains (n) | Year/local | Method | Primary antibiotics resistance (%) | |||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| A | C | M | L | Te | Multidrug resistance | |||
| Hoan | 2001/North | ADM | 0 | 0 | 38.1 | 5.8 | ||
| Vinh | 2003/North | E-test & ADM | 18.1 | 21.6 | 54.3 | |||
| Nhan and Mai | 2006/South | ADM | 0 | 38.5 | 50.8 | 9.2 | ||
| Thinh | 2009/North | DDM | 33.9 | 21.4 | 94.6 | 21.4 | ||
| Nguyet and Hanh | 2010/North | DDM | 35.5 | 26.7 | 95.5 | 17.8 | ||
| Toan | 2012/North | DDM | 43.6 | 36.6 | 94.2 | 20.9 | 56.4 | |
| Binh | 2013 | E-test | 0 | 33.0 | 69.9 | 18.4 | 5.8 | 24.3 |
| Dung | 2015 | ADM | 7.7 | 43.6 | 83.6 | 33.2 | 10.9 | 58.2 |
| Phan | 2015/Central | E-test | 0 | 34.2 | 75.3 | 35.6 | 50.7 | |
| Quek | 2016/South | E-test | 10.4 | 85.5 | 37.8 | 24.4 | ||
| Mean | 14.9 | 34.1 | 69.4 | 27.9 | 17.9 | 47.4 | ||
A, amoxicillin; C, clarithromycin; M, metronidazole; L, levofloxacin; Te, tetracycline; ADM, agar dilution method; E-test, Epsilometer test; DDM, disk diffusion method. E-test33 (AB Biodisk, Solna, Sweden), E-test34 (bioMerieux, Marcy I’Etoile, France), E-test35 (bioMerieux).
Multidrug resistance: includes resistance to at least two antibiotics;
North Vietnam + South Vietnam;
North Vietnam + Central Vietnam + South Vietnam.
Fig. 2Average rate of primary resistance with Helicobacter pylori in Vietnam from 2001 to 2016.
Rate of Secondary Antibiotic Resistance of Helicobacter pylori in Vietnam (2014–2016)
| Author/strains (n) | Year/local | Method | Primary antibiotics resistance (%) | |||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| A | C | M | L | Te | Multidrug resistance | |||
| Minh | 2014/South | ADM | 13.7 | 56.9 | 44.1 | 25.5 | 23.5 | - |
| Phan | 2015/Central | E-test | 5.3 | 73.7 | 78.9 | 63.2 | - | 78.9 |
| Hue | 2016/South | E-test | - | 94.3 | - | 48.6 | - | 45.7 |
| Mean | 9.5 | 74.9 | 61.5 | 45.7 | 23.5 | 62.3 | ||
A, amoxicillin; C, clarithromycin; M, metronidazole; L, levofloxacin; Te, tetracycline; ADM, agar dilution method; E-test, Epsilometer test.
Multidrug resistance: includes resistance to at least two antibiotics;
Clarithromycin+levofloxacin.
Rate of Antibiotic Resistance of Helicobacter pylori in Hanoi and Ho Chi Minh City-Vietnam
| Local | Antibiotic | Binh | Dung |
|---|---|---|---|
| Hanoi | Amoxicillin (A) | 0 | 3.9 |
| Clarithromycin (C) | 18.5 | 42.1 | |
| Metronidazole (M) | 70.3 | 89.5 | |
| Levofloxacin (L) | 18.5 | 21.1 | |
| Tetracycline (Te) | 7.4 | 11.8 | |
| Ho Chi Minh City | Amoxicillin (A) | 0 | 6.9 |
| Clarithromycin (C) | 49.0 | 39.2 | |
| Metronidazole (M) | 69.3 | 81.4 | |
| Levofloxacin (L) | 18.3 | 41.2 | |
| Tetracycline (Te) | 4.0 | 12.7 |
Data are presented as percentage.
Fig. 3Multidrug resistance patterns of Helicobacter pylori in Vietnam. C+M, clarithromycin+metronidazole; C+L, clarithromycin+levofloxacin; C+T, clarithromycin+tetracycline; M+L, metronidazole+levofloxacin; M+T, metronidazole+tetracycline; L+T, levofloxacin+ tetracycline.
Multivariate Analysis of Predictors for Helicobacter pylori Resistance
| Antibiotic | Parameter | Multivariate analysis | |
|---|---|---|---|
|
| |||
| OR (95% CI) | p-value | ||
| Clarithromycin (n=153) | Age ≥30 yr | 3.2 (1.3–7.7) | 0.011 |
| Previous eradication | 7.7 (1.7–34.7) | 0.008 | |
| Levofloxacin (n=154) | Age ≥40 yr | 1.9 (0.9–3.7) | 0.057 |
| Previous eradication | 1.4 (0.6–3.1) | 0.386 | |
OR, odds ratio; CI, confidence interval.
Helicobacter pylori Eradication Regimens in Vietnam45
| Regimen | Duration of therapy | |
|---|---|---|
| Triple therapy | PPI+A+C | 7 Days |
| Sequential therapy | First 5 days: PPI+A | 5 Days |
| Next 5 days: PPI+C+Ti | 5 Days | |
| Concomitant therapy | PPI+A+C+M/Ti | 10 Days |
| Bismuth quadruple therapy | PPI+M+Te+B | 14 Days |
PPI, proton pump inhibitor; A, amoxicillin; C, clarithromycin; Ti, tinidazole; M, metronidazole; Te, tetracycline; B, bismuth.